Lisata Therapeutics Completes Enrollment for Cancer Therapy Trial

Exec Edge

2024-12-11

By Karen Roman

Biopharma company Lisata Therapeutics, Inc. (Nasdaq: LSTA) said it finished patient enrollment for the next stage of its CENDIFOX trial.

The study will assess the safety and effects of combining certepetide, Lisata’s cyclic peptide candidate, with FOLFIRINOX-based therapies for pancreatic, colon, and appendiceal cancers, it stated.

“By addressing the unmet medical needs of patients with solid tumors, we aim to improve patient outcomes and augment the standard-of-care paradigm,” said Kristen K. Buck, Lisata’s EVP of Research and Development and Chief Medical Officer.

Contact:

Exec Edge

Editor@Executives-edge.com

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2490206860"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2490206860\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2490206860?lang=zh_CN&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/SXaTFhl7BKX0qz3AWRCjLw--~B/aD04MDA7dz0yODczO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/exec_edge_220/30ce7031e78a3e46f757131f82f73d8b","is_english":true,"pubTime":"2024-12-11 23:28","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2490206860","market":"us","top_or_hot":-1,"title":"Lisata Therapeutics Completes Enrollment for Cancer Therapy Trial","media":"Exec Edge","content":"<html><body><p><img height=\"800\" src=\"https://s.yimg.com/uu/api/res/1.2/yGisg_kq81Tv4sgDYyQBGQ--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/exec_edge_220/30ce7031e78a3e46f757131f82f73d8b\" width=\"2873\"/></p>\n<p>By Karen Roman</p>\n<p>Biopharma company Lisata <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>, Inc. (Nasdaq: LSTA) said it finished patient enrollment for the next stage of its CENDIFOX trial.</p>\n<p>The study will assess the safety and effects of combining certepetide, Lisata’s cyclic peptide candidate, with FOLFIRINOX-based therapies for pancreatic, colon, and appendiceal cancers, it stated.</p>\n<p>“By addressing the unmet medical needs of patients with solid tumors, we aim to improve patient outcomes and augment the standard-of-care paradigm,” said Kristen K. Buck, Lisata’s EVP of Research and Development and Chief Medical Officer.</p>\n<div>\n<div>\n  Contact:\n </div>\n</div>\n<p>Exec Edge</p>\n<p>Editor@Executives-edge.com</p></body></html>","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lisata Therapeutics Completes Enrollment for Cancer Therapy Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLisata Therapeutics Completes Enrollment for Cancer Therapy Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-11 23:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/lisata-therapeutics-completes-enrollment-cancer-152806791.html><strong>Exec Edge</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Karen Roman\nBiopharma company Lisata Therapeutics, Inc. (Nasdaq: LSTA) said it finished patient enrollment for the next stage of its CENDIFOX trial.\nThe study will assess the safety and effects of ...</p>\n\n<a href=\"https://finance.yahoo.com/news/lisata-therapeutics-completes-enrollment-cancer-152806791.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LSTA","symbol_name":"LISATA THERAPEUTICS INC","start_time":0,"source_url":"https://finance.yahoo.com/news/lisata-therapeutics-completes-enrollment-cancer-152806791.html","article_id":"2490206860","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/SXaTFhl7BKX0qz3AWRCjLw--~B/aD04MDA7dz0yODczO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/exec_edge_220/30ce7031e78a3e46f757131f82f73d8b"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2490206860","pubTimestamp":1733930886,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Biopharma company Lisata Therapeutics, Inc.  said it finished patient enrollment for the next stage of its CENDIFOX trial.The study will assess the safety and effects of combining certepetide, Lisata’s cyclic peptide candidate, with FOLFIRINOX-based therapies for pancreatic, colon, and appendiceal cancers, it stated.“By addressing the unmet medical needs of patients with solid tumors, we aim to improve patient outcomes and augment the standard-of-care paradigm,” said Kristen K. Buck, Lisata’s EVP of Research and Development and Chief Medical Officer.","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LSTA":"LISATA THERAPEUTICS INC","LENZ":"Therapeutics","BK4139":"生物科技"},"translate_title":"Lisata Therapeutics完成癌症治疗试验的入组","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"LSTA":0.9},"content_text":"By Karen Roman\nBiopharma company Lisata Therapeutics, Inc. (Nasdaq: LSTA) said it finished patient enrollment for the next stage of its CENDIFOX trial.\nThe study will assess the safety and effects of combining certepetide, Lisata’s cyclic peptide candidate, with FOLFIRINOX-based therapies for pancreatic, colon, and appendiceal cancers, it stated.\n“By addressing the unmet medical needs of patients with solid tumors, we aim to improve patient outcomes and augment the standard-of-care paradigm,” said Kristen K. Buck, Lisata’s EVP of Research and Development and Chief Medical Officer.\n\n\n  Contact:\n \n\nExec Edge\nEditor@Executives-edge.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}